GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: lamictal

First Posted Date: 2008-07-28

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 301

Registration Number: NCT00723450

Locations: 🇺🇸
GSK Investigational Site, Seattle, Washington, United States

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Pazopanib (GW786034)
Drug: Doxorubicin
Drug: Epirubicin

First Posted Date: 2008-07-25

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 111

Registration Number: NCT00722293

Locations: 🇨🇭
GSK Investigational Site, St Gallen, Switzerland

A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686

Phase 1

Completed

Conditions: Inflammatory Bowel Diseases

Interventions: Drug: GSK1399686

First Posted Date: 2008-07-24

Last Posted Date: 2017-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 87

Registration Number: NCT00721812

Locations: 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: A/turkey H5N1 vaccine
Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Biological: Placebo

First Posted Date: 2008-07-21

Last Posted Date: 2018-07-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 841

Registration Number: NCT00719043

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal vaccine GSK134612

First Posted Date: 2008-07-21

Last Posted Date: 2019-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 387

Registration Number: NCT00718666

Locations: 🇺🇸
GSK Investigational Site, Amarillo, Texas, United States

Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years

Phase 3

Completed

Conditions: Influenza Vaccines

Interventions: Biological: Fluviral®

First Posted Date: 2008-07-18

Last Posted Date: 2019-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 110

Registration Number: NCT00718120

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Nimenrix
Procedure: Blood sampling

First Posted Date: 2008-07-15

Last Posted Date: 2014-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 818

Registration Number: NCT00715910

Locations: 🇺🇸
GSK Investigational Site, Waipio, Hawaii, United States

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: GSK Biologicals' quadrivalent influenza vaccine
Biological: GSK Biologicals' trivalent influenza vaccine

First Posted Date: 2008-07-14

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 420

Registration Number: NCT00714285

Locations: 🇨🇿
GSK Investigational Site, Hradec Kralove, Czechia

Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Herpes Labialis

Interventions: Drug: New formulation
Drug: Current formulation

First Posted Date: 2008-07-09

Last Posted Date: 2018-08-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 27

Registration Number: NCT00711776

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GW642444

First Posted Date: 2008-07-08

Last Posted Date: 2017-07-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 9

Registration Number: NCT00711126

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy